Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITR-XXX
- Development stage
- Preclinical
- Lead developer
- Iteria Biopharma
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
ITR-XXX is an early-stage targeted protein degrader (TPD) being developed by Iteria Biopharma for the treatment of solid tumors. The drug is designed to induce the selective degradation of an undisclosed kinase target by utilizing the cell's internal ubiquitin-proteasome system. As a protein degrader, it aims to overcome limitations associated with traditional kinase inhibitors, such as target overexpression or the development of compensatory mutations, by completely removing the pathogenic protein rather than just inhibiting its activity. The program is currently in the IND-enabling phase of development, following Iteria's strategy of applying its TPD platform to challenging oncology targets.
- Other names
- Kinase protein degrader (Iteria Biopharma)
Beyond the preview
Go deeper on ITR-XXX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITR-XXX.